In EVPs derived from cancer cells, PD‐L1+ small EVs have been reported to be associated with the therapeutic efficacy of immune checkpoint inhibitors and prognosis because PD‐L1 is expressed on the surface of small EVs released from cancer cells and causes tumour growth by suppressing CD8+ T cell function (Theodoraki et al., 2018). This evidence concerns the gene CD274 and neoplasm.